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Summary A series of pure, monomeric porphyrins (2-8) based on porphyrin C (1) have been tested as
sensitisers for photodynamic therapy (PDT) ofcerebral glioma using the in vitro/in vivo C6 intracerebral animal
tumour model. The in vitro screening, consisting of cytotoxicity, phototoxicity (red light) and subcellular
localisation studies, revealed two sensitisers (porphyrin 7, molecular weight 863 Da and porphyrin 8, molecular
weight 889 Da), which had greater photoactivity than porphyrin C and similar photoactivity to
haematoporphyrin derivative (HpD) although at a 5-fold higher dose than HpD. Both sensitisers showed
intracellular localisation to discrete organelle sites and exhibited considerably less 'dark' cytotoxicity than
HpD. The kinetics of uptake of porphyrins 7 and 8 was studied in the mouse C6 glioma model as well as in
biopsy samples from normal brain, liver, spleen and blood. Maximal drug uptake levels in tumour occurred 9
and 6 h after intraperitoneal injection for 7 and 8 respectively, at which time the tumour to normal brain ratios
were 15:1 and 13:1 respectively. The effect of PDT using porphyrin 7 activated by the gold metal vapour laser
tuned to 627.8 nm was studied in Wistar rats bearing the intracerebral C6 glioma. At a drug dose of 10 mg
porphyrin 7 kg-' body weight and laser doses of up to 400 J cm-2 light, selective tumour kill with sparing of
normal brain was achieved, with a maximal depth of tumour kill of 1.77+0.40 mm. Irradiation following a
higher drug dose of 75 mg porphyrin 7 kg-' body weight resulted in a greater depth of tumour kill, but also
significantly increased the likelihood and extent of necrosis in normal brain.
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Photodynamic therapy (PDT) is a novel cancer treatment
that depends on the retention of a photosensitiser by tumour
tissue, followed by treatment ofthe tumour with laser light of
an appropriate wavelength to activate the sensitiser (Gomer,
1989). Haematoporphyrin derivative (HpD) and the more
purified fraction Photofrin remain the most widely used
photosensitisers for the PDT of solid tumours (Dougherty,
1987), and particularly for cerebral tumours (Kaye and Hill,
1992). However, they both lack a number of properties that
have been proposed to be present in an ideal sensitiser
(MacRobert et al., 1989). Neither of the substances is
composed of a single pure sensitiser, and, despite many
laboratory investigations, the definitive active molecular
component remains in doubt. In addition, both sensitisers
produced prolonged skin photosensitisation.
Porphyrin C is a sensitiser that has shown tumour-
localising and photosensitising properties both in vitro and
in vivo (Liang et al., 1984; Henderson et al., 1985; Scourides
et al., 1985, 1986). Recently Kaye (1988) investigated the
effectiveness of porphyrin C as a sensitiser of cerebral glioma
because of its potential advantages over HpD, namely the
lack of prolonged skin sensitisation and the ability to prepare
porphyrin C as a pure compound. Using a C6 glioma model
in rats and mice porphyrin C was shown by fluorescence
analysis to be selectively taken up by the glioma, with only
slight fluorescence detected in the brain tissue adjacent to the
tumour and no fluorescence in normal brain structures within
an intact blood -brain barrier (BBB). Quantitative uptake
studies using a '5S-labelled derivative of porphyrin C showed
that maximal uptake into intracerebral tumour occurred 1 h
after intravenous administration, at which time the ratio of
sensitiser levels in tumour relative to normal brain was 1000:1
(Kaye, 1988). In PDT studies using Wistar rats bearing the
C6 intracerebral glioma, porphyrin C was found to cause
selective tumour kill at doses of up to 100 mg kg-' and 200
J cm-2 628 nm light, with a measured depth of tumour kill of
3.1 mm, as compared with 4.5 mm for HpD (Kaye, 1988).
Kaye also examined the in vitro sensitivity of C6 glioma cells
to photosensitisation with porphyrin C and found that it was
significantly less photoactive than HpD at equivalent doses
and suggested that a 10-fold increase of porphyrin C over
HpD was required to achieve the same in vitro cell kill. This
difference in photoactivity was proposed to be related to the
subcellular localising property of the two porphyrins. HpD
localises both within the cytoplasm and in subcellular
organelles of glioma cells (Hill et al., 1992a), whereas
porphyrin C remains extracellular, and seems only to loosely
associate to the outer cell membrane (Kaye, 1988).
Thus in summary, both the in vitro and in vivo studies on
porphyrin C, have shown that it is a less powerful
photosensitiser than HpD at equivalent doses. A photo-
sensitiser of equal purity and similar pharmacokinetics to
porphyrin C, but with the tumour sensitising properties of
HpD, would be desirable. This paper reports on several
analogues of porphyrin C that have been tested as sensitisers
for PDT of cerebral glioma using the C6 tumour model.
Materials and methods
Porphyrins
Porphyrin C (1, Table I) was synthesised according to the
procedure of Scourides et al. (1986), and an adaptation of
this protocol was used for the synthesis of the porphyrin C
analogues (2-8) as previously described (Karagianis et al.,
1993). HpD was supplied by the Queen Elizabeth Hospital,
Adelaide, Australia. Before use, a standard solution of each
porphyrin was prepared at a concentration of 5 mg ml-' in
isotonic saline. Porphyrin C and analogues (2-8) had similar
absorbance spectra and extinction coefficients to HpD
(Karagianis et al., 1993).
Cells
The C6 rat glioma cell line was obtained from the American
Type Culture Collection (Rockville, MD, USA) and was
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maintained as a monolayer culture in RPMI-1640 medium
[Commonwealth Serum Laboratories (CSL), Parkville,
Australia] supplemented with 10% fetal calf serum (FCS)
(Gibco, Australia) and 2 mM L-glutamine (CSL). Standard
culture conditions of 37°C and 5% carbon dioxide were used.
Colony survival assay and dark toxicity
C6 rat glioma cells were grown in 80 cm2 flasks (Nunclon) for
3 days after subculturing. While in the logarithmic phase of
growth, the cells were harvested via the removal of the spent
medium, washed with 10 ml of phosphate-buffered saline
(PBS) (CSL), detached with 3 ml of tryspin-versene (CSL)
and then diluted with 7 ml of RPMI-1640 medium containing
10% FCS before being centrifuged at 2000 g for 5 min. The
pellet was resuspended in 10 ml of culture medium and the
viable cells counted using a haemocytometer and trypan blue
exclusion test. Typically, a single cell suspension of 200 viable
cells was seeded to 25 cm2 tissue-culture flasks (Nunclon)
prewrapped in aluminium foil, and incubated for 6 h to allow
for cellular attachment to the base ofthe flask. Varying doses
of porphyrin photosensitiser (0-100 ig ml-') were added to
the appropriate foil-wrapped flasks and the cells incubated
for 18 h, washed twice with 2 ml of medium to remove
exogenous porphyrin and further incubated for 7 days in
2 ml of fresh medium. Colonies were fixed using triplicate
3 ml aliquots ofmethanol-glacial acetic acid mixture (7:3, v/
v) over three 15 min periods, and then stained with 2 ml of
crystal violet solution (1%, w/v) over a 1 h period. Flasks
were washed with cold water to remove excess dye and the
colonies (greater than 50 cells) scored using a lightbox or
inverted microscope. Each experiment was performed in
triplicate and duplicated on a different day.
In vitro phototoxicity (red-light)
C6 cells were harvested and seeded into 25 cm2 flasks as
described in the colony survival assay (above). The cells were
incubated in the presence of 50 gm of porphyrin for 18 h,
washed twice with 2 ml of medium and resuspended in 2 ml
of fresh medium before exposure to light. The foil was
removed, and the flasks placed on a lightbox and exposed to
red filtered light from a broad-band fluorescent source (NEC
15 W standard cool white, Nippon Electrical, Tokyo, Japan).
The red-light output was achieved by placing filters between
the flasks and the opaque Perspex top of the lightbox. This
filter combination (Rosco Supergel No.15 and No.25 filters,
Masson Photographics, Bulleen, Australia) allowed transmis-
sion only of light above 600 nm, at an energy dose of
0.2 J min-' cm-'. The cells were exposed to the red filtered
light at room temperature for varying times between 0 and 60
min and the flasks then re-wrapped in aluminium foil and
incubated for a further 7 days at 37°C and 5% carbon
dioxide. Adherent colonies were fixed, stained and scored as
described in the colony survival assay. The dose dependence
of photoxicity was also investigated for the porphyrin
photosensitisers 7 and 8 over the range 0-100 ,g ml-'. The
experimental procedures and conditions were as above except
the red-light exposure time was kept constant (i.e. 60 min).
After 7 days incubation, adherent colonies were fixed, stained
and scored as described above.
Fluorescence microscopy
Typically, 104 cells per flask were seeded into foil-wrapped
25 cm2 Nunclon flasks and incubated for at least 6 h before
addition of the porphyrin. All porphyrin solutions were
diluted in culture medium to a concentration of 10 ug ml -
before incubation with the cells for either 3 or 24 h. The
medium was then removed and the adherent cells washed
twice with medium to remove any exogenous porphyrin. The
base of the flask was removed with a hot scalpel and a
coverslip (18 x 15 mm) placed on the culture area to make a
wet mount, and the edges of the coverslip sealed with nail
polish. The intracellular localised porphyrin was detected
using a Biorad MRC 500 confocal laser scanning fluorescent
microscope operating at an excitation wavelength of 488 nm
from an argon ion laser, with the emission monitored above
600 nm. Fluorescence images were obtained photographically
using Mitsubishi CK lOOL film. Control images of C6 cells
not incubated with porphyrin showed no detectable
fluorescence.
Animals and tumours
Adult CBA mice, 5-8 weeks old, were injected with 106 C6
rat glioma cells using the method developed by Kaye et al.
(1986). This procedure resulted in the establishment of
discrete xenografted intracerebral C6 tumours. Intracranial
implantation of 105 C6 glioma cells into adult male Wistar
rats weighing between 200 and 300 g was performed using the
method developed by Kaye et al. (1985).
Porphyrin administration in tumour-bearing mice
A standard solution of the appropriate porphyrin was
prepared at a concentration of 5 mg ml-' in isotonic saline
at pH 7.4, and the solution sterilised by passing it through a
0.2 ,um millipore filter (Schleicher & Schull, Germany). Ten
days after tumour implantation, CBA mice were injected via
the i.p. route with a dose of 75 mg kg-' body weight of the
appropriate porphyrin in a total volume of 0.4 ml of saline,
and sacrificed at time points between 2h and 24 h after drug
administration. Following sacrifice, the entire brain, liver and
spleen were excised from the animal and a blood sample
collected (100 jil). The brain was sectioned through the
tumour and a tissue biopsy sample of normal brain and brain
tumour was taken. The porphyrin content of the tissues was
then determined using the porphyrin extraction assay
described below.
Porphyrin extraction assay
Uptake of porphyrins into tissue was measured using the
method of Kessel and Cheng (1985) as modified by Hill et al.
(1990, 1992). Typically, a preweighed amount of tissue (20-
40 mg) was suspended in 6 ml of 50 mM Hepes-10 mM cetyl
trimethyl ammonium bromide (CTAB), pH 7.4 and
homogenised for 30 s. Triplicate 2 ml aliquots were
removed, and each was mixed with 5 ml of a chloroform-
methanol mixture (1:1, v/v), then thoroughly vortexed and
centrifuged at 2000 g for 5 min. The upper aqueous phase
and a layer of cell debris at the interface between upper and
lower phases were discarded and then the lower organic
phase was collected. All extracted porphyrins were present in
the lower phase with no porphyrins detectable in the upper
phase by fluorescence measurements. Similarly no porphyrins
were detectable in the debris layer after re-extraction. The
chloroform lower phase was then evaporated to dryness
under a stream of nitrogen gas, and the resulting residue was
suspended in 2.5 ml of 50 mM hepes- 10 mM CTAB, pH 7.4.
The absorbance of these solutions was then determined at
400 nm relative to a control blank that determined the level
of endogenous porphyrin extracted from unsensitised tissue.
Those extracts with higher absorbance values were diluted
with 50 mM Hepes-10 mM CTAB, pH 7.4, such that their
final absorbance was equal to 0.15 absorbance units in a 1 cm
path length cell. This dilution step overcame the problem of
concentration-dependent quenching of the fluorescence
emission by either the extracted porphyrin or haemoglobin
that was co-extracted with the porphyrin from the tissue
samples. Quantitative fluorescence measurements of the
extracted porphyrin were made using an excitation wave-
length of 402 nm and an emission wavelength of 624 nm in a
Perkin Elmer LS 30 spectrofluorimeter equipped with a red-
sensitive R928 Hamamatsu photomultiplier tube (Perkin-
Elmer, Australia). The total amount of porphyrin in each
tissue sample was determined relative to a standard curve of
known amounts of porphyrin subjected to the above
extraction procedure.Porphyrin C analogues for PDT of cerebral glioma
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PDT
PDT of C6 tumour-bearing Wistar rats sensitised with
porphyrin 7 was performed using the method established by
Kaye and Morstyn (1987). Briefly, adult male tumour-bearing
Wistar rats were injected via the i.p. route with either 10 or
75 mg porphyrin 7 kg-1 body weight 10 days after tumour
implantation. At 8.5 h after porphyrin administration, the rats
were anaesthetised using methoxyflurane inhalation followed
by i.p. administration of 3.6% (w/v) chloral hydrate at a dose
of 1% (v/w) body weight. Following the induction of
anaesthesia, the scalp and the overlying tissue was reflected
and a 0.16 cm2 craniotomy performed using a high-speed
dental drill. This craniotomy was placed 1 mm anterior to the
previous tumour injection site so that the craniotomy was over
the area of the tumour. The dura was not opened. Laser
therapy was administered 9 h after porphyrin administration.
The animals were treated with doses of 0, 50, 100, 200 or 400
J cm-2 laser light following a dose of 10 mg porphyrin 7 kg-',
and 0, 50, 100 or 200 J cm-2 laser light following a dose of
75 mg kg-'. The light was delivered via a flat-cut 600 ,um
quartz optical fibre connected to a gold metal vapour laser
(Quentron, Adelaide, Australia) generating light of 627.8 nm.
The fibre tip was held at a distance of 3-4 mm over the area
of the craniotomy so that the red-light spot completely
covered the exposed dural surface, but was within the margins
of the craniotomy. Power output was measured using an
integrating sphere connected to a power meter to enable
dosimetry calculations. Power output at the fibre tip ranged
from 0.8 to 1.1 W, resulting in a power density at the dural
surface of between 4 and 6.9 W cm-2, and irradiation times
ranging from approximately 7 to 80 s. The surface ofthe brain
was irrigated with normal saline at room temperature during
the period ofirradiation, as this has previously been shown by
Kaye and Morstyn (1987) to prevent necrosis due to
hyperthermia at these power densities. After irradiation, the
craniotomy site was covered with a single layer of Surgicel
(Johnson and Johnson, Australia) and the incision closed with
wound clips. The animals were sacrificed 5 days after laser
treatment and the brains removed. The brain specimens were
fixed in 10% formaldehyde, sectioned and stained with
haematoxylin and eosin. The extent of cerebral oedema,
Table I Structures, cytotoxicity (IC50) and phototoxicity (IT50)
properties of the porphyrins used in this study.
IC50' IT50b
Porphyrin R (#M) (min)
1 (Porphyrin C) SCH2CH(NH2)CO2H 708 >60
2 SCH2CH(NHCOCH3)CO2H >900 >60
3 S(CH2)2CO2H 710 >60
4 S(CH2)2NH2 209 >60
5 S(CH2)2N(CH3)2 142 >60
6 SCH2CHCONHCH2CO2H 290 >60
NHCO(CH2)2CH(NH2)CO2H
7 SCH(CO2H)CH2CO2H 100 45
8 SCH(CH3)CONHCH2CO2H 197 55
9 (HpD)c 24 50
a Concentration of drug(gM) required to inhibit colony growth of
C6 rat glioma cells in culture by 50% following 18h incubation in the
absence oflight. b Time (min) required to inhibit colony growth ofC6
rat glioma cells in culture by 50% following 18h incubation in the
absence oflight and subsequent exposure to red light at a drug dose of
50 /M for porphyrins 1 - 8 and 10 gM for HpD. c HpD is a complex
mixture ofporphyrins; molar concentration is based on a monomeric
HpD average molecular weight of 580 Da.
cerebral necrosis or tumour kill was measured using a
graticule micrometer as previously described (Kaye and
Morstyn, 1987).
PDT on normal rat brain
The experimental procedure and conditions were identical to
those described above except that normal non-tumour-
bearing adult male Wistar rats were used.
Results
'Dark' cytoxicity
The inherent 'dark' cytoxicity of the respective porphyrin
photosensitisers on the C6 glioma cell line was determined
using colony formation as an end point and survival
percentages were calculated relative to an untreated control
in each treatment group. Comparative toxicities were
determined at the concentration at which a 50% reduction
in colony numbers was observed (IC50 level).The IC50 values
expressed in gM concentration for all the porphyrins studied
are shown in Table I. All of the porphyrin thioethers (1-8)
were far less toxic than porphyrin 9 (HpD; IC50 of 24 giM,
assuming HpD existed in the monomeric form), however, the
porphyrin C analogues 4-8 were more toxic than porphyrin
C (1, IC50 of 708 gM) and its N,NY-diacetyl derivative (2, IC50
of >900 gM). Porphyrin 3 showed similar cytotoxicity to
porphyrin C.
The cytotoxicity of porphyrin photosensitisers was
investigated in order to determine suitable dose levels to be
used in examining their red-light phototoxicity properties on
the C6 glioma model. From the above data, a standard
concentration of 50 JgM was chosen for the porphyrin
thioethers and 10 gM for HpD.
Phototoxicity (red-light)
The phototoxicity of the respective porphyrin photosensitisers
on the C6 glioma cell line was examined after exposure to
filtered light of greater than 600 nm. The dependence of red-
light phototoxicity on exposure time is shown in Figure 1 for
porphyrins 7, 8 and 9 (HpD). The cell viability of the control
group was unaffected after 60 min of red-light exposure (data
not shown in Figure 1). Comparative phototoxicities are
expressed as the exposure time at which 50% reduction in
colony numbers was observed (IT50 level, Table I). Porphyrin
C (1) and the analogues 2-6 were relatively inefficient in
C',
0
0 10 20 30 40 50 60
Exposure time (min)
Figure 1 Phototoxicity of porphyrins. The colony survival of C6
rat glioma cells incubated in medium containing porphyrin 7 (,
43pgml-1, 50gM), porphyrin 8 (0, 44.5jugml-, 50pM) or HpD
(O, 5.8 igml-1, 10gM, assuming monomeric molecular weight of
580 Da) for 18h, then washed with porphyrin-free medium before
irradiation with red light for the times indicated. Each data point
was performed in triplicate. Data values are expressed as the per
cent of the mean number of colonies at 0min exposure for each
sensitiser. Bars represent one standard deviation of the mean.Porphyrin C analogues for PDT of cerebral glioma
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Figure 2 The dose-dependent phototoxicity of C6 rat glioma
cells incubated for 18 h in medium containing porphyrins 7 (0) or
8 (0), and then washed in porphyrin-free medium before
irradiation with red light for 60min. Each data point was
performed in triplicate, and for each curve values are expressed as
the per cent of the number of colonies surviving following a drug
dose of 0 pgml and 60min light exposure. Bars represent one
standard deviation of the mean.
photosensitising C6 cells under red-light conditions. How-
ever, C6 cells treated with an equimolar concentration of
porphyrins 7 and 8 respectively were killed at a similar rate to
HpD-treated cells, although concentrations of these porphyr-
in C analogues five times that of HpD were required to
mediate the same degree of cell kill (Figure 1). Exposure to
60 min of red light resulted in a 78% reduction in colony
survival for porphyrin 7, 54% for porphyrin 8 and 70% for
HpD (Figure 1).
Photosensitisers 7 and 8 demonstrated a consistent dose-
dependent photoactivated toxicity following 60 min of red-
light exposure over the dose range 0-100 pg ml-' (Figure 2).
A 50% reduction in colony survival was observed at
33 pg ml-' for porphyrin 7 and 42 pg ml-' (47 pM) for
porphyrin 8, with 100% lethality at doses exceeding
70 pg ml - (81 pM) for porphyrin 7 and 100 pg ml
(112 gM) for porphyrin 8.
Subcellular localisation
The subcellular localisation of the porphyrin thioethers in C6
glioma cells was investigated by confocal laser scanning
fluorescence microscopy, a novel microscopic method that
has been used for identifying the subcellular localisation of
fluorescent porphyrin compounds (Woodburn et al., 1991;
Hill et al., 1992a,b). Porphyrin localisation was studied at a
concentration of 10 pug ml-' with incubation times of 3 and
24 h respectively. With the exception of porphyrin C (1) and
N,N'-diacetyl porphyrin C (2), both of which associated only
with the external surface of the cell membrane, all porphyrins
localised intracellularly. Following 3 h incubation, porphyrins
3-7 showed a similar pattern of localisation, in which
fluorescence was detected both throughout the cytoplasm and
in a distinct punctate pattern, possibly associated with
subcellular organelles (Figure 3a). In contrast, porphyrin 8
appeared to be localised exclusively to subcellular organelles.
By comparison with the distribution of porphyrins known to
localise specifically to mitochondria (Woodburn et al., 1991;
Hill et al., 1992a,b), the site of localisation may be
mitochondrial (Figure 3b), although it is possible that the
localisation may be in other structures such as lysosomes.
After 24 h incubation the intracellular fluorescence of all
porphyrins was most pronounced around the nuclear
membrane. There was no porphyrin fluorescence detected in
the nucleus during any of these experiments, a finding which
was in agreement with previous studies (Woodburn et al.,
1991; Hill et al., 1992a,b).
b
Figure 3 The confocal laser scanning micrograph of C6 rat
glioma cells incubated for 3 h with porphyrin 7 (a) or porphyrin 8
(b) at a concentration of 10 pgml The scale bar in each panel
represents m.
Biodistribution and tumour localisation
Of the porphyrin C analogues evaluated in vitro, only
porphyrins 7 and 8 exhibited significant red-light photo-
toxicity, and therefore only these were selected for further in
vivo uptake studies using the C6 glioma model.
The kinetics of uptake of the photosensitisers 7 and 8 were
studied in a mouse model of cerebral glioma to determine the
time at which there was the greatest differential between the
level of sensitiser in the tumour and in the normal brain. In
addition, the distribution of the photosensitisers in various
other organs was also examined. The pharmacokinetics of
uptake of porphyrins 7 and 8 into tumour and various other
organs is summarised in Table II. For porphyrin 7 the uptake
into tumour was maximal 9 h after administration
(17.6+ 1.3 pg g 'tissue), at which time the level in normal
brain in the contralateral hemisphere was 1.2+0.5 pg g-',
representing a tumour to normal brain ratio of approximately
15:1. A photograph taken under Woods lamp exposure
demonstrates the localisation of porphyrin 7 in the glioma at
the time of maximal uptake (Figure 4a). The photograph
shows the discrete localisation of the photosensitiser to
intracerebral tumour, with only slight fluorescence in the
brain adjacent to tumour and no detectable fluorescence in
normal brain. This result compares favourably with an
adjacent coronal section of the same brain stained with
haematoxylin and eosin that shows demarcation of the
tumour from the normal brain (Figure 4b). It is interesting
to note that the discrete fluorescence in the upper region of
the opposite hemisphere is due to localisation of porphyrin 7








0Porphyrin C analogues for PDT of cerebral glioma
G Karagianis et a!
Table II Uptake studies of porphyrins 7 and 8 administered into C6 tumour-bearing mice at a dose of 75 mg kg-1 body
weight, respectivelya
Time
Porphyrin (h) Tumour Brain Liver Spleen Blood
7 2 5.3+±0.7 2.3+0.5 52± 11 22.5±0.9 104+ 11
4 10.2+0.7 2.0+0.4 35.6+2.4 15.0+2.8 65.3+ 18.4
9 17.6+ 1.3 1.2+0.5 25.0+4.6 8.9+ 1.4 34.2+3.7
15 14.5+ 1.0 1.6+0.3 17.6+ 1.9 6.6±0.7 21.3+6.3
24 10.0±1.2 2.0+0.2 12.1 ±2.2 4.8+ 1.8 12.1 ±0.7
8 3 12.6± 1.0 1.6+0.2 87± 1.2 40+ 12 63± 13
6 15.6+ 1.1 1.2±0.2 42± 19 18.7±5.0 39.3±6.5
9 8.6+0.8 1.5+0.1 28.6+ 1.2 13.3+ 1.4 20.1+8.0
15 3.8+0.7 1.4+0.7 16.4+4.1 6.0+3.1 9.8+ 1.7
24 0.8+0.7 0.9+0.7 7.3+ 1.3 2.6+0.5 3.2± 3.2
a Uptake values (mean ±s.d.) areexpressed asMgporphyrin g l tissue wetweight, and for blood asMgporphyrinml-1 whole
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Figure 4 Coronal section of a brain containing implanted
tumour from a mouse sensitised via the i.p. route with porphyrin
7 at a dose of 75 mgkg-1 body weight. The same section is
photographed under UV light (a) and stained with haematoxylin/
eosin (b).
the subpial plane (Figure 4b). The uptake of porphyrin 7 into
other mouse organs shows that the highest levels were
observed in the blood, with maximal uptake occurring 2 h
after injection (Table II). The amount of photosensitiser in
the blood and liver remained higher than that in the tumour
over the 24 h post-injection period.
Figure 5 The depth of tumour kill (0) or normal brain necrosis
(@) in the Wistar rat C6 glioma model following irradiation with
the gold metal vapour laser 9h after i.p. administration of
porphyrin 7 at doses of 10mgkg-1 body weight (a) and
75mgkg-1 body weight (b). The number of animals studied at
each data point was either three or four. Bars represent one
standard deviation of the mean.
Following administration of porplyrin 8 the uptake into
tumour was maximal at 6h (15.6+ 1.1 p,g g-1) at which time
the level in the surrounding normal brain was
1.2+0.2 pg g- representing a tumour to normal brain
ratio of approximately 13:1 (Table II). The uptake into other
mouse organs shows that the highest levels were observed in
the liver in the intial 4h post-injection period and the amount
in the liver, blood and spleen remained higher than that in
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PDT
Since porphyrin 7 displayed a higher tumour to normal brain
uptake ratio than porphyrin 8, it was decided to investigate
the effect of PDT using porphyrin 7 on C6 intracerebral
tumour in Wistar rats.
PDT of porphyrin 7-sensitised normal and C6 tumour-
bearing rats was carried out to establish the dosimetry
parameters within which PDT using this sensitiser could be
undertaken to obtain maximal tumour kill without damage to
surrounding normal brain.
Dependence of tumour kill and normal brain necrosis on dosage
ofphotosensitiser and light
When 10 C6 tumour cells were implanted at a depth of 1.5-
2 mm from the outer bone margin, intracerebral tumours
grew to the surface of the brain. The maximal depths of
tumour kill as a function of light dose following administra-
tion of either 10 or 75 mg porphyrin 7 kg-' body weight
respectively are shown in Figure 5. The major finding was
that the depth of tumour kill was dependent on both
sensitiser and light dose. There was no tumour kill in
sensitised animals that had not received laser treatment, nor
in sensitised animals that received 10 mg porphyrin 7 kg-'
and 50 J cm-2 red light. The depth of tumour kill was
significantly greater for both sensitiser doses following a light
irradiation of 100 J cm-2 rather than 50 J cm-2. However,
there was no significantly greater tumour kill at doses of light
greater than 100 J cm-2 following a dose of either 10 or
75 mg kg-' (Figure 5). This non-linear relationship may be
due to photobleaching of the photosensitiser at the higher
light dose (Kaye and Morstyn, 1987). An example of selective
tumour kill at doses of 10 mg kg-' sensitiser and 200 J cm-2
red light is shown in Figure 6. To determine whether the
tumour kill achieved was selective, the effect of laser light on
the normal brain was studied using non-tumour-bearing
Wistar rats sensitised with porphyrin 7.
Porphyrin 7 in doses of either 10 or 75 mg kg-' body
weight, followed 9 h later by craniotomy, but no laser
treatment, resulted in no damage to the normal brain. It has
previously been established that irradiation of saline-irrigated
unsensitised brain or tumour with laser light at doses up to
1200 J cm-2 delivered at power levels ranging from 0.05 to
1.2 W at the fibre tip produced no significant damage to
either tissue as detected by light microscopy (Kaye and
Morstyn, 1987).
There was no evidence of brain necrosis or oedema at a
sensitiser dose of 10 mg kg-' and doses of laser light up to
400 J cm-2 (Figure 5a). However, at a sensitiser dose of
75 mg kg-', significant normal brain necrosis occurred at all
light doses (Figure 5b).
Figure 6 Selective tumour kill in the Wistar rat C6 model after
irradiation with 200Jcm-2 628nm light from the gold metal
vapour laser 9h after administration of porphyrin 7 at a dose of
10mgkg-
1 body weight.
Selective photodynamic kill of cerebral tumours
The data in Figures 5 and 6 show that following doses of
10 mg porphyrin 7 kg- ' and laser doses up to 400 J cm-2,
selective tumour kill of depth 1.77+0.40 mm was achieved
without normal tissue necrosis. It is also clear from these
results that a dose of 75 mg kg-1 of porphyrin 7 caused a
greater depth of tumour kill, but also increased both the
likelihood of developing necrosis in the normal brain and the
extent of that necrosis.
Discussion
The in vitro evaluation of the porphyrin C analogues (2-8)
was used as an initial screening in order to select the most
promising photosensitisers. The results presented in this study
showed that porphyrin C (1) and the analogues (2-8) were
considerably less cytotoxic than HpD in the absence of light.
Under conditions of red-light exposure, only porphyrins 7
and 8 exhibited substantial photoactivity in comparison with
HpD, but required a dose five times higher than HpD to
achieve a similar in vitro cell kill.
Porphyrins 3-8 were shown to localise within C6 cells as
detected by fluorescence confocal microscopy, whereas
porphyrin C (1) and its N,N'-diacetyl derivative (2) showed
only minimal intracellular uptake. The lack of intracellular
incorporation of porphyrins 1 and 2 is consistent with results
obtained in previous studies (Scourides et al., 1985; Kaye,
1988). These porphyrins remain extracellular and associate
loosely to the outer cell membrane of tumour cells. This poor
cellular uptake is probably due to their extreme hydro-
philicity and consequent inability to partition into the
hydrophobic environment of the cell membrane. At the
shorter incubation time (3 h), porphyrin 8 localised
specifically to subcellular organelles, possibly either mito-
chondria or lysosomes, whereas porphyrins 3-7 localised
generally throughout the cytoplasm and in some regions in a
punctate manner. Previous studies have shown similar
patterns of intracellular localisation of other porphyrin
sensitisers (Woodburn et al., 1991; Hill et al., 1992a,b). This
disparity in localisation between porphyrin 8 and analogues
3-7 may reflect a difference in the mechanism by which these
sensitisers are taken up by the cells, although at present these
mechanisms are yet to be precisely described. The localisation
of porphyrin photosensitisers in mitochondria may be
mediated by the peripheral benzodiazepine receptor located
on the outer membrane of the mitochondria, the natural
ligands of which are believed to be porphyrins (Verma et al.,
1987). A recent structure-localisation study with porphyrins
varying in hydrophobicity and charge, suggest that porphyr-
ins that are highly cationic in nature localise in mitochondria,
whereas those with a more anionic character tend to localise
in lysosomes (Woodburn et al., 1991). However, the possible
mitochondrial localisation of porphyrin 8, which is dom-
inantly anionic in character, does not appear to be dependent
on the charge of the porphyrin molecule and therefore it can
be postulated that other factors, such as hydrophobicity,
membrane potential or receptor-mediated uptake mechanisms
may be involved. At the longer incubation time (24 h) there
was a distinct change in the intracellular localisation pattern
of the porphyrins 3-8, in which fluorescence was most
pronounced around the nuclear membrane. This shows that
migration or redistribution of the porphyrin molecules to the
nuclear membrane may occur with increasing incubation
time. Such intracellular redistribution has been reported with
other porphyrin photosensitisers (Schneckenburger et al.,
1988).
The in vivo evaluation of photosensitisers 7 and 8 in the
C6 glioma model has shown that both sensitisers are
selectively retained in tumour tissue. This was apparent
using Woods lamp exposure to induce fluorescence of the
tumour in coronal brain sections, and also by fluorescence
assay of the porphyrins extracted from tumour and brain
biopsies. Since various studies have shown that photosensi-
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tisers do not cross the BBB, the differential uptake into the
tumour as compared with normal tissue is assumed to be, at
least in part, due to the disruption of this barrier in the
tumour and its maintenance in normal regions of the brain
(Rapport, 1976; Yamada et al., 1982; Kaye et al., 1985).
However the demonstration of the extremely high tumour to
brain ratios that can be achieved using other porphyrin
sensitisers (Hill et al., 1992b) suggests that other factors apart
from just BBB breakdown must be critical in mediating
uptake. Kinetic studies showed that peak drug uptake levels
in tumour occurred at 9 and 6 h after injection for
porphyrins 7 and 8 respectively, with maximal tumour to
normal brain ratios of 15:1 and 13:1 respectively. The uptake
of HpD and porphyrin C by C6 intracerebral gliomas has
previously been studied by Kaye (1988). HpD showed
maximal uptake by fluorescence at 24 h following i.p.
administration and porphyrin C 1.5 h after i.p. injection.
Therefore, the rate of uptake of porphyrins 7 and 8 into the
tumour is slower than porphyrin C, but faster than HpD.
The difference in pharmacokinetics may reflect different
mechanisms of vascular transport, uptake and retention for
each photosensitiser. Although the sensitisers studied here did
not achieve the same ratio between tumour and normal brain
as HpD (30:1; Hill et al., 1990), porphyrin C (1000:1; Kaye,
1989) or a boronated protoporphyrin (400:1; Hill et al.,
1992a,b), this is not a great disadvantage if a clear tumour-
selective PDT response can be generated.
Preliminary PDT studies using porphyrin 7 were encoura-
ging, with selective tumour kill achieved at a dose of 10 mg
porphyrin 7 kg-' and laser doses up to 400 J cm-2, resulting
in a maximal depth of tumour kill of 1.77+0.40 mm. At the
higher dose of 75 mg porphyrin 7 kg-', significant normal
brain phototoxicity occurred. Phototoxicity to normal brain
could result from the presence of sensitiser at sufficient levels
in brain to initiate phototoxic reactions. Alternatively, it has
previously been reported that the observed depth of damage
following PDT is greater than that which could be expected
from analysis of the fluence of light, suggesting that damage
to vasculature in the irradiated tissue may result in
'downstream' infarction of tissue that is beyond the
penetrative depth of the light (Kaye and Hill, 1992). Thus
the damage to normal brain in close proximity to the tumour
could be a result of the destruction of tumour vasculature
causing associated normal tissue death. It is also possible that
the accumulation of the products of tumour destruction
following PDT may cause congestive oedamatous damage in
the adjacent normal tissue.
It has previously been shown that selective kill of cerebral
tumours by HpD using the C6 glioma model occurs at
concentrations of less than 20 mg HpD kg-' and light doses
of less than 200 J cm-2 red light (Kaye and Morstyn, 1987).
The effectiveness of porphyrin 7 at a concentration of 75
mg kg-' and light dose of 400 J cm-2, is similar to that
obtained with HpD at 10 mg kg-' and a light dose of
200 J cm-2, for which the mean depth of tumour kill was
4.5 mm (Kaye and Morstyn, 1987). In contrast, porphyrin C
has been shown to mediate tumour kill only at doses greater
than 100 mg kg-' and 200 J cm-2 red light, with a mean
depth of tumour kill of 3.1 mm (Kaye, 1988). The
preliminary results obtained with porphyrin 7 suggest that
further PDT studies at drug doses between 10 and
75 mg kg-' are required in order to determine the maximum
selective dose for this photosensitiser. However, porphyrin 7
does exhibit a greater photodynamic activity than porphyrin
C, and a similar activity to HpD in the C6 glioma model,
although possibly at lower sensitiser doses. Previous uptake
studies using HpD have shown a tumour to brain ratio of
30:1 (Hill et al., 1990; Kaye and Hill, 1992), whereas the ratio
reported here for porphyrin 7 was 15:1. It is possible that this
decreased selectivity may result in lower sensitiser and/or
light dose thresholds above which normal brain toxicity will
be evident. Future studies may address this question, which
has great relevance to increasing an understanding of PDT
dosimetry.
In conclusion, the porphyrin 7 photosensitiser may present
several advantages over HpD and Photofrin. It is a pure
compound and may, like porphyrin C, have the potential to
reduce the side-effects of cutaneous photosensitivity apparent
with HpD. In addition, since it is a single chemical species, it
would be easier to design derivatives of this compound that
may lead to an improvement in efficacy in vivo. Although the
maximum selective doses of porphyrin 7 and the subsequent
activating light are yet to be determined, preliminary results
suggest that it is a compound to be considered for future
preclinical PDT studies on cerebral glioma.
Abbreviations
PDT, photodynamic therapy; HpD, haematoporphyrin derivative;
FCS, fetal calf serum; PBS, phosphate-buffered saline; Hepes,
hydroxoyethylpiperazine-N-2-ethanesulphonic acid; CTAB, cetyl-
trimethylammonium bromide; i.p., intraperitoneal.
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